Drug Profile
TPIV 200
Alternative Names: Folate receptor alpha vaccine; Folate receptor alpha-loaded dendritic cell vaccine; FR alpha peptide vaccine; FRa peptide vaccine; FRalphaDC; HuFR-1; Multi-epitope folate receptor alpha peptide vaccine; TPIV200Latest Information Update: 02 Dec 2022
Price :
$50
*
At a glance
- Originator Mayo Clinic
- Developer Marker Therapeutics Inc; Mayo Clinic
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ovarian cancer; Triple negative breast cancer
- No development reported Fallopian tube cancer; Peritoneal cancer
Most Recent Events
- 30 Nov 2022 No development reported - Phase-II for Triple-negative-breast-cancer (Monotherapy, Second-line therapy or greater) in USA (Intradermal)
- 19 Jul 2021 Marker Therapeutics completes a phase II trial in Triple negative Breast cancer in USA (NCT02593227)
- 20 Jan 2021 Marker Therapeutics in collaboration with MedImmune and Memorial Sloan Kettering Cancer Institute completes a phase II trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) in USA (Intradermal) (NCT02764333)